PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors, adding more than two decades of healthcare investing experience. The appointment follows completion of enrollment in the Phase 2 monotherapy portion of the pivotal PYNNACLE trial of rezatapopt, with an NDA submission for accelerated approval in TP53 Y220C platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Key figures
- Drug Name
- rezatapopt
- Phase Of Trial
- Phase 2
- Nda submission timing
- first quarter of 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.